[EN] FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS<br/>[FR] HÉTÉROCYCLES FUSIONNÉS UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR 5-HT2A
申请人:[en]ONSERO THERAPEUTICS INC.
公开号:WO2023141225A1
公开(公告)日:2023-07-27
The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as neurological disorders. Pharmaceutical compositions and methods of making various azaindole and benzisoxazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.